Medtide Inc. (HKG:3880)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
22.10
-0.30 (-1.34%)
Jun 18, 2026, 2:15 PM HKT
Market Cap3.18B
Revenue (ttm)634.40M +28.9%
Net Income241.89M +267.3%
EPS1.81 +332.1%
Shares Out 141.80M
PE Ratio12.36
Forward PE10.62
Dividendn/a
Ex-Dividend Daten/a
Volume73,600
Open22.50
Previous Close22.40
Day's Range21.94 - 22.70
52-Week Range19.00 - 41.72
Betan/a
AnalystsHold
Price Target29.21 (+32.17%)
Earnings DateAug 28, 2026

About Medtide

Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, pre-clinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products. Its research and development technology platforms include OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 566
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3880
Full Company Profile

Financial Performance

In 2025, Medtide's revenue was 570.09 million, an increase of 28.91% compared to the previous year's 442.23 million. Earnings were 217.37 million, an increase of 267.35%.

Financial numbers in CNY Financial Statements